Treatment with apixaban (Eliquis, Bristol-Myers Squibb/Pfizer), regardless of dosage, was associated with significantly less major bleeding compared with warfarin in a particularly high-risk ...

DURHAM, NC — Projected lifetime treatment with the oral anticoagulant apixaban (Eliquis, Bristol-Myers Squibb/Pfizer) appears to be cost-effective vs warfarin for patients with atrial fibrillation, ...

At both 6 months and 12 months follow-up, the rivaroxaban group was found to have more of these events than the apixaban group. Credit: Getty Images. In patients with atrial fibrillation and valvular ...

The factor Xa inhibitor apixaban is noninferior to conventional therapy with enoxaparin and a vitamin K antagonist in patients with acute venous thromboembolism (VTE). The study, published online July ...

Please provide your email address to receive an email when new articles are posted on . Apixaban was not superior to standard of care antithrombotic treatment for preventing thrombotic or bleeding ...

For patients with HIV and atrial fibrillation, this study found that apixaban was associated with less bleeding when compared with warfarin and rivaroxaban. Data remain inconclusive regarding ...

PRINCETON, N.J. & NEW YORK--(BUSINESS WIRE)-- Bristol-Myers Squibb Company (NYSE: BMY) and Pfizer Inc. (NYSE: PFE) today announced that the ADVANCE-3 study results, published in The New England ...

Please provide your email address to receive an email when new articles are posted on . Apixaban tied to less stroke and bleeding in patients with/without dementia vs. dabigatran, rivaroxaban or ...

LAS VEGAS, NV—The first day of VIVA 2017 began with some timely insights into pharmacotherapy with non-vitamin K oral anticoagulants (NOACs) in patients with deep vein thrombosis (DVT), and a look ...

Warfarin, blood thinner There are limited published data on the efficacy and safety of direct-acting oral anticoagulants (DOACs) in patients with end-stage renal disease (ESRD) on dialysis and atrial ...

A large-scale trial finds that apixaban, a new anticoagulant drug, is superior to the standard drug warfarin for preventing stroke and systemic embolism in patients with atrial fibrillation. Moreover, ...

The European Committee for Medicinal Products for Human Use (CHMP) has recommended approval for apixaban (Eliquis, Pfizer and BristolMyers Squibb) for atrial fibrillation (AF). The drug is already ...